Zimbabwe has turned down a significant US healthcare agreement worth $367m (272 million pounds) over five years because of Washington's demand for confidential information.
The decision was revealed after a government memo dated December was leaked, indicating that Head of State Emmerson Mnangagwa felt the arrangement was "unbalanced".
An official spokesperson has since explained that the United States was seeking biological samples for scientific study and commercial purposes but was unwilling to guarantee the resulting advantages from any future medical innovations.
"We are forced to start the challenging and unfortunate process of scaling back our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the United States had furnished more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for more negotiations to secure a agreement suitable to all parties so the country's vital HIV treatment initiative can continue.
Broader Context
Zimbabwe's decision follows a similar situation in Kenya, where a high court blocked a similar health funding agreement following concerns were filed about the security of citizens' medical information.
After returning to office last year, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).
The agency had administered aid for the American government, but Trump claimed its spending was "wasteful" and his administration was seeking government-to-government agreements to boost transparency and responsibility.
Based on statements, Sixteen nations in Africa have to date agreed to similar agreements, representing more than $18.3bn in new funding.
Specifics of the Rejected Agreement
This assistance for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this partnership might have yielded significant advantages for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving HIV treatment through American-funded programmes," Tremont commented.
However, official spokesman Nick Mangwana said the proposed deal was "asymmetrical".
"Zimbabwe was being asked to surrender its genetic material and health information for a long time, without any corresponding guarantee of benefiting from any medical innovations – such as new medicines or tests – that could result from that provided information," he stated.
"Effectively, our nation would supply the basic resources for scientific discovery without any certainty that the end products would be available to our population if a future pandemic arise."
Sovereignty and Global Health
He also said that the US's withdrawal from the global health body and its push of bilateral deals were disrupting structures already set up through the global organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme created to deal with future global health emergencies.
"This system is intended to ensure that when a nation contributes its information, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the resources to develop them."
These objections over the US deal "should not be misconstrued as opposition to America," he added.
"We welcome ongoing dialogue with our US partners on how future collaboration could be structured in a way that respects the independence and dignity of each country."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it acknowledged the government's concerns, but urged that negotiations need to persist given that much of the country's HIV programmes relied on external financing.
"In cases where specific concerns exist, such as those relating to data governance or implementation frameworks, these can often be addressed through detailed discussion and mutually agreed protections," it commented.
This impasse underscores the complex challenges between accepting crucial international aid and safeguarding local interests in an ever more data-driven world.